China
Africa
Explore chapters and articles related to this topic
Adenoviral Gene Transfer of the Herpes Virus Thymidine Kinase Gene for Treating Gliomas
Published in Eric Wickstrom, Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, 2020
Jane Β. Alavi, Jason G. Smith, Stephen L. Eck
All of the patients with malignant gliomas had progression of their tumors following standard therapy (i.e., surgery and radiation therapy). Patients underwent stereotactic injection of the virus into the tumor (from 108 to 1010 pfu) followed by systemic GCV. One week after their initial treatment the tumors were partially resected and a second dose of adenovirus was injected into the residual tumor bed. GCV therapy was continued for two more weeks.
Disposition and Metabolism of Drugs of Dependence
Published in S.J. Mulé, Henry Brill, Chemical and Biological Aspects of Drug Dependence, 2019
Study on the regional distribution of d – and l -isomers after stereotaxic injection of 10 μg of 14C-labeled drug with mannitol as an inert marker into the lateral cerebral ventricle of rats showed no significant difference in the accumulation and diffusion of the two isomers in different regions of the brain, although analgesia was produced only in those animals injected with l -isomer.263
Stereotaxic-assisted gene therapy in Alzheimer’s and Parkinson’s diseases: therapeutic potentials and clinical frontiers
Published in Expert Review of Neurotherapeutics, 2022
Samar O. El Ganainy, Tony Cijsouw, Mennatallah A. Ali, Susanne Schoch, Amira Sayed Hanafy
In general, the benefits of stereotaxis, especially in the long-term management of symptoms and disease progression, outweigh the risks of undergoing general anesthesia and brain surgery, especially in older patients. The continuing drive for an applicable and feasible stereotaxic-assisted gene delivery relies on utilizing the least invasive incisions, minimalizing surgical risks, shortening the duration of surgery and recovery time, and achieving the highest possible therapeutic efficacy. In comparison to AD, PD represents a more successful candidate disease for stereotaxic intervention given the focality of disease pathogenesis in the nigrostriatal system, mainly within the putamen area. In AD, the forebrain is considered the main region of interest for stereotaxic injection of potential treatments. Based on the higher frequency and success rate of clinical trials in PD over AD, it can be concluded that sterotaxically delivered gene-based therapeutics are potentially more promising in PD rather than AD, at least till now.
Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy’s history, efficacy and application in humans
Published in International Journal of Hyperthermia, 2018
Keon Mahmoudi, Alexandros Bouras, Dominique Bozec, Robert Ivkov, Constantinos Hadjipanayis
A few drawbacks have been reported regarding MHT use for patients with GBM. One drawback is the removal of dental fillings, implants and crowns, as well as other metallic materials within 40 cm of the treatment area prior to AMF exposure [58]. Implantation of pacemakers and defibrillators is a contraindication due to the electromagnetic interference caused by an AMF [128]. Another drawback is the inability to monitor the tumour response to treatment by MRI due to artefacts generated by the high concentration of the injected MNPs. Instead of MRI, fluoro-ethyl-tyrosine positron emission tomography/computerised tomography (FET-PET/CT) and single-photon emission computerised tomography (SPECT) can be used to monitor tumour growth and recurrence in these patients [58,127]. However, MRI can still detect new tumour lesions either outside the MNP deposit areas or in the contralateral brain hemisphere. Furthermore, as discussed before, stereotactic injection may not be the best delivery option for the MNPs due to anecdotal reports of leak back of the MNPs along the stereotactic site and inadequate distribution within and around the tumour area. Despite these drawbacks, the benefits seen in the limited number of clinical trials using MHT as a treatment modality for GBM patients indicate that MHT may have a larger impact in the future care of GBM patients.